Noveome Biotherapeutics
Noveome Biotherapeutics is a biopharmaceutical company focused on developing ST266, a novel biologic with diverse applications in ophthalmology, neurology, and dermatology, backed by 51 U.S. patents and significant global patents.
Company Overview
Noveome Biotherapeutics is a biopharmaceutical company engaged in developing innovative therapies for a range of medical conditions. The company focuses on ST266, a novel biologic with potential applications in ophthalmology, neurology, dermatology, and other fields. Noveome has received rare pediatric disease designation and orphan drug designation for the treatment of necrotizing enterocolitis in neonates. The company's research spans multiple clinical trials, and it holds a robust intellectual property portfolio protecting ST266 and its production process.
Products
Noveome Biotherapeutics is developing ST266, a novel biologic derived from amnion-derived epithelial cells from full-term placentas. ST266 is rich in biologically active proteins and factors that are crucial for neuroprotection, inflammation modulation, cell recovery, and healing. The product can be administered through various routes including topical, intracameral, intraoral, intravenous, and intranasal. Completed clinical trials have demonstrated its safety and efficacy in conditions like persistent corneal epithelial defects and glaucoma.
Clinical Trials
Noveome Biotherapeutics has undertaken several clinical trials to evaluate the efficacy and safety of ST266. A Phase 2 clinical trial demonstrated the benefit of ST266 in healing persistent corneal epithelial defects. Additionally, a Phase 1 clinical trial established the safety of intranasally delivered ST266 in glaucoma suspect patients. The company is currently conducting a Phase 1 trial to assess the safety of intravenously delivered ST266 in COVID-19 patients.
Intellectual Property
Noveome Biotherapeutics has a strong intellectual property portfolio, consisting of 51 U.S. patents and over 40 granted patents in major global markets including Europe, Japan, China, and Canada. These patents cover various aspects of ST266, including the cells and processes for producing it. This extensive patent portfolio highlights the company's commitment to protecting its innovative biologic and proprietary production methods.
Funding and Financials
Noveome Biotherapeutics has successfully raised substantial funding to support its clinical trials and development initiatives. The company raised $40 million in Series E financing, which is being utilized to advance clinical trials, including those related to necrotizing enterocolitis. This financial backing underscores investor confidence in the potential of ST266 and the company's broader pipeline of therapeutic applications.